Cyramza plus Tagrisso significantly extended PFS in TKI-naïve EGFR-mutant NSCLC patients compared to Tagrisso alone, with a median PFS of 24.8 vs. 15.6 months. PFS benefits were consistent across ...
Tagrisso has been approved for some adults with locally advanced, unresectable stage 3 non-small cell lung cancer. The Food and Drug Administration (FDA) has approved Tagrisso (osimertinib) for adults ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback